Biosimilars Clinical Development In-house training in Amsterdam.

Views:
 
     
 

Presentation Description

Biosimilars Clinical Development In-house training in Amsterdam. Yes it is happening, The best masterclass on Biosimilar in Amsterdam is going to start soon. Overview In this Biosimilars Clinical Development Masterclass participants will Assessment of PK, PD, Immunogencity and safety in biosimilar studies. place Amsterdam, The Neatherlands https://aureliusglobalmasterclass.com/events/advancing-biosimilars-clinical-development/

Comments

Presentation Transcript

Slide 1:

Aurelius Global Masterclass Learn From The Best In The World

Slide 2:

I am here to show you some of our work like who are we and what we do. I am Sumit Peer CEO Of Aurelius Global Masterclass Hello!

Slide 3:

Aurelius Corporate Solutions wants to be seen and accepted as one stop shop for all industry specific master-classes across the globe, thereby making the line managers well versed with the acceptable technology and business practices, adopted worldwide. About us

Slide 4:

So as you know about us. Let’s begin the journey of masterclasses we provided for years. As we are specialist in this field So let’s go

Slide 5:

Well Plugging And Abandonment Clinical Trials Regulation Biosimilars Clinical Development The Masterclasses We Provided Is Taught By The Best Professionals In There Fields. Some Of Our Masterclass

Slide 6:

In this Biosimilars Clinical Development Masterclass participants will Introduction to biosimilar pathways in EU and US: experiences so far In this Biosimilars Clinical Development Masterclass participants will Totality of the evidence and role of analytical data In this Biosimilars Clinical Development Masterclass participants will Assessment of PK, PD, Immunogencity and safety in biosimilar studies In this Biosimilars Clinical Development Masterclass participants will Tailored clinical development path Biosimilars Clinical Development

Slide 7:

EMA and FDA expectations for biosimilar clinical studies What factors should be considered in design of the study Working with analytics: understanding impact of residual uncertainties and differences Selection of patient population Study specific considerations for assessment of safety and immunogenicity Interchangeability and where switching data will be required KEY TAKEAWAYS 

Slide 8:

A Picture Is Worth A Thousand Words

Slide 10:

Instagram Facebook YouTube Our Social Medial Platforms

Slide 11:

Venue & Date Start Time 9:00 am November 18, 2019 Finish Time 5:00 pm November 19, 2019 Address Amsterdam, The Netherlands

Slide 12:

Europe 19,450000 Region

Slide 13:

Email: aureliusglobalmasterclass.com Phone:  +44 2032 398083 Any questions? Thanks!

authorStream Live Help